21/07/2026
Ottawa, Ontario — Tuesday July 21, 2026
ADHD affects millions of children worldwide, yet no two children experience the condition in the same way.
A major review led by Phillippe Robaey examined research on the management of ADHD in children and adolescents published between 2019 and 2025. The review shows how the field is evolving, with new evidence reshaping our understanding of how ADHD develops, changes over time, and responds to different treatments.
“One of the biggest shifts in ADHD research has been the recognition that there is no single ADHD profile or treatment pathway. Advances in genetics, developmental science, and clinical research are helping us better understand why children and young people experience ADHD differently, bringing us closer to more personalized approaches to care.” — Dr. Phillippe Robaey
The latest research suggests that ADHD is best understood as a chronic and often fluctuating condition rather than a fixed childhood disorder. As children grow and develop, their symptoms, challenges, and support needs may change, highlighting the importance of ongoing care and monitoring.
The review also highlights both the promise and current limitations of emerging digital ADHD tools – while interest in these technologies is growing, many still lack the evidence needed to support widespread clinical use.
Together, these findings point toward a future where ADHD care is increasingly tailored to each child, helping families and clinicians identify the right mix of supports at the right time. While stimulant medications remain the most effective treatment for core ADHD symptoms, they are rarely sufficient on their own. For many children, combining pharmacological, behavioral, school-based, family-based, and healthy lifestyle interventions, tailored to their individual needs, can provide complementary benefits.